Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBT (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed EBT for 13 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 71.26% to -$2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $47.2 million, a 209.21% increase, with the full-year FY2024 number at -$44.6 million, up 9.45% from a year prior.
  • EBT was -$2.9 million for Q3 2025 at Theravance Biopharma, down from $73.2 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $114.4 million in Q4 2022 to a low of -$79.5 million in Q1 2021.
  • A 5-year average of -$11.4 million and a median of -$14.1 million in 2025 define the central range for EBT.
  • Peak YoY movement for EBT: plummeted 73.1% in 2023, then skyrocketed 580.95% in 2025.
  • Theravance Biopharma's EBT stood at -$55.8 million in 2021, then skyrocketed by 305.27% to $114.4 million in 2022, then plummeted by 106.63% to -$7.6 million in 2023, then fell by 17.88% to -$8.9 million in 2024, then skyrocketed by 67.68% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's EBT are -$2.9 million (Q3 2025), $73.2 million (Q2 2025), and -$14.1 million (Q1 2025).